Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Item

http://www.wikidata.org/entity/Q40143100

Q40143100

about

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Item

http://www.wikidata.org/entity/Q40143100

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Switching to the single-tablet ...... 96 results of STRATEGY-NNRTI.

@en

type

Item

label

Switching to the single-tablet ...... 96 results of STRATEGY-NNRTI.

@en

prefLabel

Switching to the single-tablet ...... 96 results of STRATEGY-NNRTI.

@en

P1476

Switching to the single-tablet ...... k 96 results of STRATEGY-NNRTI

@en

P2093

Andrea Antinori

http://www.w3.org/2001/XMLSchema#string

Anton Pozniak

http://www.w3.org/2001/XMLSchema#string

Damian J McColl

http://www.w3.org/2001/XMLSchema#string

David Piontkowsky

http://www.w3.org/2001/XMLSchema#string

Douglas Ward

http://www.w3.org/2001/XMLSchema#string

Jason Flamm

http://www.w3.org/2001/XMLSchema#string

Javier Szwarcberg

http://www.w3.org/2001/XMLSchema#string

Kristen Andreatta

http://www.w3.org/2001/XMLSchema#string

Thai Nguyen-Cleary

http://www.w3.org/2001/XMLSchema#string

William Garner

http://www.w3.org/2001/XMLSchema#string

P2860

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Prediction of creatinine clearance from serum creatinine

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Development and validation of a self-completed HIV symptom index.

Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Rever

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

P304

141-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15284336.2017.1338844

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Juan Berenguer

Pierre Côté

Mark Bloch

P577

2017-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28689453

http://www.w3.org/2001/XMLSchema#string

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

about

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698